Primadex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Primadex

Property Description
Active Ingredients Sulphamethoxazole, Trimethoprim
Pharmacological Class Combination Antibiotic (Sulfonamide/Diaminopyrimidine)
Forms Tablet, Oral Suspension, IV Solution
Origin Synthetic (Chemotherapeutic Agent)
General Purpose To eliminate susceptible bacteria

What is Co-trimoxazole (Primadex)?

Primadex is a trade name for the synthetic, prescription-only fixed-dose combination antibiotic known generically as Co-trimoxazole. The medicine belongs to the anti-infective agent class, which encompasses two chemical groups: a sulfonamide and a diaminopyrimidine. Other widely known brands containing this exact formulation include Bactrim and Septra.

This agent is defined by its pairing of two active ingredients in a predetermined ratio, a unique design that is clinically recognized for providing effective, targeted action against susceptible microorganisms. The combination structure enhances the therapeutic profile of both components.

Composition and Available Forms

The formulation contains the two key active ingredients: Sulphamethoxazole and Trimethoprim. Trimethoprim is classified as a dihydrofolate reductase inhibitor, functioning through enzyme interruption. The fixed combination is highly valued because it achieves a more powerful result than either substance alone.

Co-trimoxazole is provided in several dosage forms, facilitating administration based on necessity. These include oral preparations like tablets and an oral suspension for standard use, as well as a solution designated for intravenous (IV) infusion typically reserved for systemic use in hospital settings.

The General Purpose of This Combination Antibiotic

The general purpose of Co-trimoxazole is to control and eliminate susceptible bacteria by inhibiting their ability to grow and reproduce. This function is achieved through a sequential blockade of the microbial folic acid metabolism pathway. Due to this dual intervention, the combination is engineered to be bactericidal (microbe-killing) against susceptible pathogens, often utilized when treating complex or widespread infections. The efficacy of this combined approach is why the agent is often preferred over single-drug regimens.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Primadex?

Possible side effects and safety information

Regulatory documents structure the safety profile of Primadex (Co-trimoxazole) by classifying adverse effects according to frequency and the body system affected. These classifications are used by government health authorities to communicate potential risks.

Frequency-Classified Adverse Reactions

The most frequently documented adverse effects include hyperkalaemia (very common), an increase in blood potassium levels, along with headache, nausea, diarrhoea, and rash, which are classified as common. Less common effects include vomiting. Rarer, but serious, documented reactions include fulminant hepatic necrosis, severe blood disorders like agranulocytosis and aplastic anaemia, and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

System-Organ Safety Constraints

Adverse reactions are formally grouped into system-organ classes. Documented effects involve the Blood and Lymphatic System (various anemias), Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders (including photosensitivity), and Renal and Urinary Disorders. Official labeling notes that the highest risk for severe skin reactions is generally within the first weeks of treatment.

Population-Specific Constraints

Official prescribing information includes specific limitations. The medicine is contraindicated in infants less than two months of age and in patients with severe renal or hepatic impairment. Due to the potential for crystalluria, maintaining adequate urinary output is required as a safety measure. Patients with G-6-PD deficiency are noted to be at risk for haemolysis.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents state that an overdose of Primadex (Co-trimoxazole) may result in documented clinical manifestations including gastrointestinal effects such as anorexia and vomiting, neurological signs like confusion and loss of consciousness, and systemic findings such as fever and hematuria (blood in the urine). Laboratory findings may include electrolyte abnormalities like hyperkalemia or hyponatremia.

Overdose is associated with the potential for severe or life-threatening outcomes, which include severe blood dyscrasias (agranulocytosis), fulminant hepatic necrosis, and severe reactions such as SJS or TEN. Rare syndromes like HLH have also been documented. Immediate medical attention must be sought for a suspected overdose, and the medication must be immediately discontinued upon the first sign of a serious reaction, such as a rash or fever.

Management is primarily symptomatic and supportive. No specific antidote is known for the overall overdose. However, Folinic acid (Leucovorin) is documented for use in reversing hematological toxicity. Close monitoring of serum electrolytes and ensuring adequate urinary output are required, particularly in high-risk populations like the elderly or those with severe renal or hepatic impairment.

Therapeutic Uses of Primadex

What Primadex Treats: Main Uses and Benefits

Primadex is commonly used to manage symptoms caused by certain infections. The medication is relevant for easing symptoms and may assist with short-term symptomatic support during acute episodes.

The medication is frequently utilized for help with acute conditions presenting with symptoms of Urinary Tract Infections (UTIs), certain types of bronchitis, ear infections, and specific enteric (digestive) infections.

A key benefit for patients is symptomatic relief. As a patient might describe their experience:

“It helps ease symptom clusters related to physical discomfort, such as the burning sensation during urination or persistent coughing, which may interfere with daily functioning.”

For these symptomatic conditions, Primadex supports general well-being and assists with maintaining functional stability during symptomatic phases. It provides supportive relief when symptoms become temporarily overwhelming, helping patients cope more steadily with difficult episodes.


Quick Fact: Relief for Symptoms that interfere with daily functioning

Primadex is relevant for easing symptoms in multiple body systems, helping manage the temporary physiological strain and acute manifestations of illness in the urinary, respiratory, and digestive tracts.

Eligibility and Restrictions for Use

Who Can and Cannot Use Primadex?

Primadex (Co-trimoxazole) eligibility is strictly defined by regulatory authorities and centers on age, underlying health status, and known sensitivities. The medicine is contraindicated and must not be used by several population groups.

Absolute Non-Eligibility (Contraindicated)

  • Infants younger than 2 months of age are prohibited from use.
  • Patients with known hypersensitivity or allergy to trimethoprim or sulfonamides.
  • Patients with documented severe hepatic impairment or severe renal insufficiency where drug concentrations cannot be monitored.
  • Individuals with megaloblastic anemia due to folate deficiency, or those with acute porphyria.

Conditional or Restricted Use

  • Pregnancy and Lactation: Use is generally not recommended during the entire pregnancy and is contraindicated at term. Use is also restricted in nursing mothers if the infant is jaundiced or premature.
  • Geriatric Patients: Use requires particular caution due to an increased risk of adverse reactions and higher likelihood of coexisting organ function impairment.
  • Comorbidities: Caution is required in patients with G6PD deficiency or a history of severe skin reactions associated with sulfonamides.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Primadex (Co-trimoxazole) details specific constraints when co-administered with other medicines or products, based on regulatory documentation.


Formally Contraindicated Combinations

Co-administration is contraindicated with Dofetilide due to the risk of serious ventricular arrhythmias stemming from increased plasma concentrations. Regulatory documents also restrict concomitant use with Clozapine and Methenamine.


Drug-Drug Interaction Patterns

Primadex is documented to alter the concentrations of several medicines. It can potentiate the anticoagulant activity of Warfarin through the stereo-selective inhibition of its metabolism and prolong the half-life of Phenytoin. The medicine increases plasma exposure of drugs such as Digoxin, particularly in elderly patients, and Lamivudine, which is associated with a 40% increase in its systemic exposure.


Pharmacodynamic and Additive Risks

The profile notes several additive pharmacodynamic effects. Combining Primadex with ACE inhibitors or Potassium-Sparing Diuretics may result in clinically relevant hyperkalemia. Co-administration with Methotrexate or other anti-folate drugs is associated with an increased risk of severe haematological reactions. Furthermore, an increased risk of thrombocytopenia is documented for elderly patients receiving concurrent thiazide diuretics. The medicine can also cause a false elevation of laboratory results for serum creatinine.

Mechanism of Action

The pharmacological action of Primadex (Co-trimoxazole) is achieved through a coordinated, two-stage inhibition that targets the essential metabolic processes of susceptible bacteria.

Sequential Blockade of Folic Acid Synthesis

This mechanism involves two primary biological targets: the bacterial enzymes Dihydropteroate Synthase (DHPS) and Dihydrofolate Reductase (DHFR). Sulphamethoxazole acts as a competitive inhibitor of DHPS, while Trimethoprim inhibits DHFR. Acting sequentially, these components create a complete arrest of the de novo folic acid pathway. This cascade is important because it leads to the immediate depletion of Tetrahydrofolic Acid (THF), a cofactor essential for DNA and protein formation in the microbe.

Synergistic Disruption of Microbial Proliferation

The combination exploits synergy, a mechanistic domain where the two inhibitors' combined effect is greater than their individual actions. Sulphamethoxazole creates a substrate deficit for Trimethoprim's target, mutually amplifying the overall inhibition and ensuring a transition from growth-stalling (bacteriostatic) to a definitive bactericidal (cell-killing) physiological effect against susceptible pathogens.

Constraint on Renal Marker Clearance

The drug's mechanism also includes a secondary constraint: Trimethoprim competitively inhibits organic cation transporters in the kidney tubules that are responsible for clearing creatinine. This engagement leads to a measurable, apparent increase in serum creatinine levels by blocking its secretion, constraining the use of this marker to accurately assess Glomerular Filtration Rate (GFR) without reflecting an actual change in the kidney's core filtration function.

Dosage and Administration Information

How to Use Primadex (Co-trimoxazole)

The use of Primadex (sulfamethoxazole and trimethoprim) is directed by official prescribing guidelines, which establish the approved route, dosage, frequency, and duration of therapy.

Administration Routes and Forms

Primadex is administered via the oral route using tablets (standard and double strength) or an oral suspension. It is also available for intravenous (IV) infusion in hospital settings for systemic use or when oral therapy is not feasible. IV infusion must be administered slowly over 60 to 90 minutes; rapid injection is forbidden.

Standard Dosing and Frequency

The standard adult dose for many acute conditions is one Double Strength (DS) tablet (800 mg SMX / 160 mg TMP) taken twice daily (every 12 hours). For severe needs, such as treatment of Pneumocystis jirovecii infections, higher doses based on 15-20 mg/kg/day of the trimethoprim component are required, typically divided into three or four doses daily. Treatment duration typically ranges from a minimum of 5 days up to 14 to 21 days, depending on the specific regimen.

Population/Condition Dosing Guideline Frequency
Standard Adult Dose 800 mg SMX / 160 mg TMP Every 12 hours
Renal Impairment ( CrCl 15–30 mL/min) Half the usual dosage Every 12 hours or once daily
Pediatric Patients Dose is based on body weight ( mg/kg) Every 12 hours

Contextual Instructions

The medicine may be taken with food or drink to minimize the potential for gastrointestinal disturbances. Adequate fluid intake is essential during treatment to help prevent crystalluria. If a dose is missed, take it as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be omitted; a double dose must never be taken. IV solutions must be diluted in a compatible solution, such as D5W, prior to administration.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Primadex

Evidence for Use in Acute Infections: UTIs, AOM, and Enteric Infections

Research exploring the profile of Primadex (Co-trimoxazole) was studied for its use in short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were conducted for conditions involving periods of heightened symptoms, such as Urinary Tract Infections (UTIs), acute Enteric Infections, and Acute Otitis Media (AOM), or ear infections, in children. The trials monitored specific outcomes related to systemic or functional imbalance, including the measured eradication of bacteria and patient-reported outcomes describing perceived discomfort.

In these comparative trials, research examined the rate at which bacteria were measured as eliminated (microbiological success) alongside the monitoring of patient-reported discomfort. Findings describe patterns observed in the measured outcomes across the studied cohorts. What remains uncertain involves the long-term patterns, as follow-up durations were limited to the acute treatment period. Data also show patterns related to antimicrobial resistance in common pathogens, which can affect the generalizability of results over time.

Evidence for Use in Serious Systemic Infections: PJP

The research landscape includes extensive controlled clinical trials for Pneumocystis jirovecii Pneumonia (PJP), a serious systemic infection. This medicine was evaluated in specific cohorts of immunosuppressed adults and children for both acute treatment and long-term prevention (prophylaxis). Studies monitored outcomes reflecting daily functioning or activity level, all-cause vital status, and the measured rate of therapeutic failure. In these trials, research describes patterns in measured survival and clinical improvement over the acute treatment interval, with findings indicating continued study in this area.

Key Evidence Gaps and Areas of Uncertainty

Research highlights what is known and what is still uncertain about this medicine. A critical gap noted in scientific literature is the impact of continually developing antimicrobial resistance on the measured outcomes globally; this challenge can affect the reliability of older trial data. Data for certain groups remain insufficient. For instance, while children are included in many trials, regulatory reviews indicate that limited information is available regarding the measured outcomes of repeated use of the medicine in children under two years old. Furthermore, comparative evidence is lacking for certain newer agents, and certainty remains low for long-term safety patterns outside of the specific long-term prophylaxis studies. The research provides context but not individual predictions.

Key Studies & References

  1. Sulfamethoxazole and Trimethoprim: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Primadex (FAQ)

Q: Is Primadex considered a first-line treatment for the condition it treats?

A: Official documents describe the medicine's use for specific approved infections, such as urinary tract infections and Pneumocystis jirovecii pneumonia (PCP). Regulatory guidelines state that its use may sometimes be reserved for situations where it offers a specific advantage or is otherwise justified. Its clinical placement is often based on external factors like patterns of bacterial resistance in a region.

Q: Does Primadex affect mood or cause emotional changes?

A: Official labeling for the drug lists a range of documented psychiatric adverse reactions. These include reports of depression, apathy, nervousness, and hallucinations. If emotional or mood changes are noted, official guidance recommends consulting with a healthcare professional.

Q: What are the common reasons why a doctor might discontinue Primadex?

A: Official prescribing information establishes contraindications, which are non-eligibility reasons why the medicine must not be used initially (e.g., severe organ impairment). Separately, official documents list serious adverse reactions, such as severe skin conditions or blood disorders. These serious events are documented clinical reasons that require the immediate cessation of therapy.

Q: What is the typical duration that a person stays on Primadex?

A: The duration of use is not fixed and varies based on the purpose of the treatment. For acute infections, official dosing typically lasts between 5 days and 14 or 21 days. However, when used for prevention (prophylaxis) of certain infections, it may be taken for the entire length of the period at risk.

Q: Can Primadex cause sleep disturbances or insomnia?

A: Yes, official safety labeling includes insomnia (difficulty falling or staying asleep) among the documented adverse reactions for the medicine. This information is found in the adverse reactions section of the official product information.

Q: Does alcohol consumption need to be avoided completely while taking Primadex?

A: Official patient information notes that taking this medicine with ethanol (alcohol) is generally not recommended. This is due to the potential for an adverse reaction, which includes symptoms like flushing and palpitations.

Q: How does Primadex affect other medications used for chronic conditions?

A: Official documents outline interactions with various medicines used for long-term health management. For example, it can increase the concentration of drugs like Digoxin and Lamivudine in the blood. It also potentiates the effect of Warfarin and increases the risk of hyperkalemia (high potassium) when combined with ACE inhibitors or similar drugs.

Q: Is Primadex found in breast milk and is it safe during breastfeeding?

A: The drug is found to achieve measurable levels in breast milk. Its use is contraindicated (must not be used) in certain infants, including those under two months of age, premature infants, or those with jaundice or G6PD deficiency. This is due to a documented potential risk of serious blood disorders and other complications in the infant.

Q: Why is Primadex sometimes described as a 'prophylactic' medicine?

A: Regulatory documents include specific instructions and dosing guidelines for the prophylaxis of certain serious infections. Prophylaxis means preventing an infection before it occurs. A key example is its long-term use for the prevention of Pneumocystis jirovecii Pneumonia (PJP) in susceptible patient groups.

Q: Have there been any recent significant research updates or new indications for Primadex?

A: Government regulatory bodies, such as the FDA, have issued updated safety warnings and labeling changes concerning the medicine. These updates include cautions regarding the risk of rare, but serious, lung injuries, such as acute respiratory failure and acute eosinophilic pneumonia.

Q: Is there an official patient leaflet or package insert for Primadex I can view?

A: Yes, official resources such as the NIH MedlinePlus and the FDA provide patient information derived directly from the full regulatory label. These resources offer descriptions and key safety information that align with the official prescribing documents.

Q: Is Primadex still effective if taken for several years?

A: Long-term administration is sometimes explored in studies. Official guidance notes that appropriate hematologic monitoring (blood tests) is necessary during extended periods of use.

Q: Why do some people online say Primadex did not work for them?

A: Official sources indicate that the development of antimicrobial resistance is a known factor that can influence treatment outcomes. Clinical guidelines emphasize that the medicine is only effective against infections caused by susceptible bacteria.

Q: Is the brand name Primadex exactly the same as the generic version?

A: Official sources describe this medicine generically as the fixed-dose combination sulfamethoxazole-trimethoprim. Generic versions are required to contain the exact same active ingredients in the same combination as the branded product. The key difference between brand and generic is typically in the inactive ingredients.

Q: Can people with liver disease use Primadex?

A: Regulatory labeling states that severe hepatic impairment (severe liver disease) is an absolute contraindication, meaning the medicine must not be used in this circumstance. If a patient has other forms of liver disease, the medicine is advised to be used with caution.

Q: What is the distinction between a common side effect and a serious adverse event for Primadex?

A: Official regulatory documents classify adverse events into two groups based on severity and frequency. Common Side Effects (e.g., headache, nausea) are those reported frequently, while Serious Adverse Reactions (e.g., severe skin reactions, severe blood disorders, liver failure) are rarer but require immediate medical attention.

Q: How does Primadex interact with birth control pills?

A: Official interaction profiles note a theoretical possibility of reduced effectiveness of estrogen-containing medications, such as some oral contraceptives. This is due to a potential interference with how the body recycles hormones. A healthcare provider can offer guidance on necessary adjustments to contraception.

Q: Is Primadex a controlled substance?

A: No, Primadex ( sulfamethoxazole-trimethoprim) is classified by government authorities as an antibacterial combination. It is not listed as a DEA-scheduled controlled substance.

Q: Is it common to have headaches when starting Primadex?

A: Yes, headache is listed in the official safety information as a common adverse effect. For serious adverse effects, the highest risk for developing severe skin reactions is generally noted to be within the first few weeks of treatment.

Q: Are there specific symptoms that require immediate medical attention while on Primadex?

A: Official patient information explicitly lists signs that warrant immediate medical attention. These include unusual bleeding or bruising, jaundice (yellowing of the skin or eyes), fever, severe rash, and mouth sores. These symptoms are often highlighted in regulatory documents as requiring immediate review.

Q: Why is the mechanism of action of Primadex important for patients to know?

A: The drug's mechanism involves two components acting in synergy to kill bacteria, which is the basis for its bactericidal (microbe-killing) effect. Understanding this allows patients to appreciate why guidelines stress using the medicine only for susceptible bacteria, a practice essential for reducing the spread of drug-resistant bacteria.

Q: Can Primadex be used by people with a history of heart issues?

A: The medicine is contraindicated (must not be used) with the heart rhythm drug Dofetilide. Caution is also advised for older patients taking drugs for heart conditions, such as ACE inhibitors, due to a documented increased risk of severe hyperkalemia (high potassium levels in the blood).

How should Primadex be stored and disposed of?

Storage Conditions

Primadex (sulfamethoxazole and trimethoprim) must be stored at Controlled Room Temperature, defined as 68 F to 77 F (20 C to 25 C). The medicine must be protected from light and kept away from excessive heat and moisture. Storage must be maintained in the container it was dispensed in, which must be tightly closed.

Specific prohibitions apply: the oral forms must not be frozen, and the concentrated injection solution must not be refrigerated. If the intravenous solution is diluted, it has limited stability and must be used within a few hours.

Child Safety and Disposal

Regulatory labeling requires that this medicine be kept out of the reach of children. Unused or expired Primadex must be disposed of according to official regulatory guidance, such as utilizing a drug take-back program. It is specified that the product should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Primadex found in:

A-Z Index: